Architecture, immunophenotype, and consequences of AITL

Slides:

Advertisements

Similar presentations

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Chapter 16 Circulation. Section 2 Blood – Blood is made up of four components: plasma, red blood cells, white blood cells, and platelets – Plasma – Red.

CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Characterization and treatment of chronic active Epstein- Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S.

Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent.

Fig. 2. Histopathological findings for initial angioimmunoblastic T-cell lymphoma (AITL) of lymph node (A~C) and secondary diffuse large B-cell lymphoma.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Gene therapy: efficient targeting of hematopoietic stem cells

Uncontrolled Wnt signaling causes leukemia

GVHD-associated immunodeficiency: soil or seed?

Gene expression profiling of peripheral T-cell lymphoma including γδ T-cell lymphoma by Kana Miyazaki, Motoko Yamaguchi, Hiroshi Imai, Tohru Kobayashi,

MBL: mostly benign lymphocytes, but…

Hydroxyurea makes inflammation “just right”?

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

“Vitamin hypothesis”: explanation for allergy increase?

Bulging glands? Blame it on B cells

Types of lymphoid tissues

Fledgling prognostic markers in CLL

by Timothy P. Hughes, and David M. Ross

How I treat autoimmune hemolytic anemias in adults

Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt-like” lymphomas from naive B cells by Delin Zhu, Chen Feng Qi,

It's all in the timing by Linda J. Bendall Blood

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Thomas S. Uldrick, and Richard F. Little

by Nataliya Melnyk, and Jonathan Harrison

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

BTK inhibition in myeloma: targeting the seed and the soil

Cancer makes new friends with old tricks

BRAF inhibitor: targeted therapy in hairy cell leukemia

A cell by any other name by Narla Mohandas Blood

Superior Survival after Autologous vs

T regulatory cells turn on T regulatory cells

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

Darwinian evolution and tiding clones in multiple myeloma

SOX11 holds mantle cell lymphoma’s key to home

Targeting kinases in CML CLL

Deep mining of the RBC proteome

Has the T cell bitten off more than it can chew?

Basophils take a slice of IRF8 pie

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

ROCK and Rho(ll) in bone marrow

Lymphocyte homing: The scent of a follicle

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

A new red cell shape helps the clot

B Cells and Transplantation: An Educational Resource

by Geling Li, Emily Waite, and Julie Wolfson

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

by Christine L. Kempton, and Amanda B. Payne

HoxA9 directly regulates cell cycle control genes.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Histopathology and bcl-2 immunohistochemistry of in situ follicular lymphoma.(A-B) Low-power view of H&E-stained (A) and bcl-2–stained (B) sections showing.

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Anti-CD20-IL-21 fusokine: the tail wags the dog

Influence of the tumor microenvironment on FL

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Model of the accumulation of Treg cells in human tumors.

Pure red cell aplasia by Robert T. Means Blood

How I treat early-relapsing follicular lymphoma

Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

by Lucy A. Godley, and Akiko Shimamura

Initial treatment of CLL: integrating biology and functional status

Proposed biology of PBL. The GC reaction occurs in the primary follicle. Proposed biology of PBL. The GC reaction occurs in the primary follicle. Naïve.

Diastolic dysfunction in sickle cell

Normal pathway of B12 absorption and cellular uptake.

A schematic approach to a patient with suspected RS

Presentation transcript:

Architecture, immunophenotype, and consequences of AITL Architecture, immunophenotype, and consequences of AITL. (A) Lymph node effacement devoid of follicles with characteristic CXCL13+ T cells. Architecture, immunophenotype, and consequences of AITL. (A) Lymph node effacement devoid of follicles with characteristic CXCL13+ T cells. (B) An illustration of the cellular components of the microenvironment and immunophenotype in AITL including HEVs, EBV+ B cells, and TFH. The B-cell activation leads to consequences commonly of AIHA and hypergammaglobulinemia (PGUS). Matthew A. Lunning, and Julie M. Vose Blood 2017;129:1095-1102 ©2017 by American Society of Hematology